Hypertension and cardiometabolic multimorbidity: an analysis of 3.4 million participants from the global May Measurement Month blood pressure screening campaign Authors: Carolina Janssen-Telders, Markus Schlaich, Aletta E Schutte, George S Stergiou, Neil R Poulter, Thomas Beaney Published: 2026 ABSTRACT AbstractIntroductionHypertension is a principal risk factor for cardiometabolic multimorbidity (CMM) but evidence regarding the prevalence and management of hypertension among people with CMM is scarce. May Measurement Month (MMM) is the largest annual global campaign collecting data on blood pressure (BP) and other cardiometabolic conditions. This study aimed to understand how hypertension prevalence, treatment, and control vary among combinations of cardiometabolic conditions.MethodsIn this cross-sectional study, 4 million MMM adult participants (≥18 years) across 105 countries were screened with triplicate BP measurement and information on lifestyle and cardiovascular risk factors. Participants were recruited using opportunistic convenience sampling. CMM was defined as the co-existence of ≥2 of three cardiometabolic conditions: diabetes, myocardial infarction and stroke. Eight subgroups were established for all possible combinations of cardiometabolic conditions.ResultsThis analysis included 3 397 746 participants. Of these, 408 162 had at least one cardiometabolic condition and 91 222 (2.7% of the total cohort) had CMM. Among individuals with CMM, 56.1% had hypertension. As the number of cardiometabolic conditions increased, the percentage of participants with co-existing hypertension increased, along with the percentage of participants on BP-lowering treatment. Despite higher treatment rates in hypertensives with CMM (85.6%) vs those with no cardiometabolic conditions (45.4%), BP control rates (<140/90 mm Hg) were similar to those with no conditions or a single condition. Among subgroups, those with all three conditions were most likely to have co-existing hypertension and take BP-lowering medication.ConclusionsThe burden of hypertension increases with the number of cardiometabolic conditions and varies across subgroups. Treatment and control rates are suboptimal in those with CMM, and efforts are needed to improve BP control of high-risk populations with diabetes, heart disease or stroke.Keywords: Cross-Sectional Studies, Cardiovascular Diseases, Humans, Prevalence, Hypertension WHAT IS ALREADY KNOWN ON THIS TOPIC Existing data on hypertension in patients with cardiometabolic multimorbidity are limited due to the under-representation of many serious co-existing conditions in large clinical trials, relying on smaller studies with homogeneous population groups and covering limited geographic regions. Existing data on hypertension in patients with cardiometabolic multimorbidity are limited due to the under-representation of many serious co-existing conditions in large clinical trials, relying on smaller studies with homogeneous population groups and covering limited geographic regions. Most studies focus on the number of conditions rather than their specific combinations, posing a challenge to understand the complex interplay and to improve management. Most studies focus on the number of conditions rather than their specific combinations, posing a challenge to understand the complex interplay and to improve management. WHAT THIS STUDY ADDS This study which analyses data on 3.4 million participants from 105 countries is the largest of its kind and provides new insights into the burden of hypertension in patients with different combinations of cardiometabolic conditions. This study which analyses data on 3.4 million participants from 105 countries is the largest of its kind and provides new insights into the burden of hypertension in patients with different combinations of cardiometabolic conditions. The focus on both the number and combinations of the three most prevalent conditions in cardiometabolic multimorbidity provides innovative knowledge on the burden of hypertension in those suffering from different combinations of cardiometabolic multimorbidity. The focus on both the number and combinations of the three most prevalent conditions in cardiometabolic multimorbidity provides innovative knowledge on the burden of hypertension in those suffering from different combinations of cardiometabolic multimorbidity. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY We found that individuals with cardiometabolic multimorbidity were more likely to have hypertension and receive blood pressure (BP)-lowering treatment, yet a significant portion remains untreated or uncontrolled worldwide. We found that individuals with cardiometabolic multimorbidity were more likely to have hypertension and receive blood pressure (BP)-lowering treatment, yet a significant portion remains untreated or uncontrolled worldwide. These results highlight the need for more targeted hypertension management strategies in this high-risk population to improve BP treatment and control outcomes and thereby reduce major adverse cardiovascular events. These results highlight the need for more targeted hypertension management strategies in this high-risk population to improve BP treatment and control outcomes and thereby reduce major adverse cardiovascular events. Introduction Multimorbidity, defined as the coexistence of two or more long-term conditions, is associated with increased morbidity, mortality and healthcare costs.1 2 In recent decades, the prevalence of multimorbidity has become a global challenge due to an ageing population and increased prevalence of long-term conditions.3 The rise in multimorbidity prevalence emphasises the need to understand common risk factors for development and shared strategies for prevention and treatment.4 5 Metabolic and cardiovascular diseases (CVD) are known to co-exist and are large contributors to the overall prevalence of multimorbidity.1 6 The term cardiometabolic multimorbidity (CMM) is often used to identify people with a history of two or more metabolic and/or cardiovascular conditions, of which the most prevalent conditions are ischaemic heart disease, stroke and diabetes mellitus.1 Shared risk factors for cardiometabolic diseases include older age, excess weight, dyslipidaemia, raised blood pressure (BP), deprived socioeconomic status, smoking and genetic predisposition.2 3 7 8 Raised BP is the single largest contributor to the global burden of disease and mortality worldwide, accounting for 10.9 million hypertension-related deaths in 2021.9 Accordingly, raised BP is the most important risk factor for the development and progression of CVD and its adverse impact is increasing annually, playing a significant role in the increased prevalence of CMM.8 10 As such, people with CMM are more often hypertensive than people with no cardiometabolic conditions, which further increases associated morbidity and mortality rates.811,13 However, to date, the relationship between CMM and hypertension remains understudied at a global level, particularly in low- and middle-income countries. May Measurement Month (MMM) is an annual global campaign aiming to increase awareness of high BP and the importance of BP measurement. In the three campaigns conducted in 2017, 2018 and 2019, over 4.2 million adult participants had their BP screened and data collected on lifestyle factors, demographic characteristics and history of selected cardiometabolic conditions.14,16 The data obtained have resulted in the largest dataset in the world on BP and related cardiometabolic disease and risk factors, providing the potential for epidemiological analyses both at global and regional levels. In this study, we aimed to understand how hypertension prevalence, treatment and control vary globally among combinations of three cardiometabolic conditions (diabetes, myocardial infarction (MI) and stroke), using pooled data from MMM 2017–2019. Methods Study design A total of 4 214 663 voluntary participants (≥18 years) were screened during the MMM campaigns of 2017, 2018 and 2019 from 105 countries using opportunistic, convenience sampling. Data from the three campaign years were pooled to increase sample size and statistical power, as the convenience sampling method used does not allow reliable assessment of trends over time. Three seated BP readings were measured at 1 min intervals from either the left or right arm and a questionnaire was used to collect data from each participant on demographics (age, sex and ethnicity), lifestyle factors (alcohol intake and whether currently smoking) and cardiometabolic conditions (a history of MI, a history of stroke or diabetes). Data collected at the screening sites were entered either via a bespoke web-based or mobile app, available in six languages, or recorded on paper and transcribed electronically. Informed consent was obtained from all participants. Raised BP was defined as a systolic BP ≥140 mm Hg and/or a diastolic BP ≥90 mm Hg based on the mean of the second and third BP readings. Hypertension was defined as having raised BP or taking antihypertensive medication. Uncontrolled BP was defined as having a systolic BP ≥140 mm Hg and/or a diastolic BP ≥90 mm Hg when taking antihypertensive medication. CMM was defined as having two or more of three cardiometabolic conditions: MI, stroke and diabetes. Participants were divided into eight subgroups representing all possible combinations of the three cardiometabolic conditions: (1) no cardiometabolic conditions, (2) MI only, (3) stroke only, (4) diabetes only, (5) MI and stroke, (6) MI and diabetes, (7) stroke and diabetes and (8) all three conditions (stroke, MI and diabetes). Height and weight were either measured at the screening site or self-reported if measuring equipment was not available. Body mass index (BMI) was calculated following the standard definition of weight (kg)/height² (m²) and categorised into four different groups according to strata recommended by the WHO: underweight (BMI under 18.5 kg/m2), healthy weight (BMI 18.5–24.9 kg/m2), overweight (BMI 25.0–29.9 kg/m2) and obese (BMI ≥30.0 kg/m2).17 Countries were grouped into seven United Nations classified geographical regions.18 Data handling Collected data were cleaned either locally at each site or centrally following data submission using the same cleaning criteria and cut-off values, which were similar across the protocols of 2017–2019. Data on 625 962 participants were excluded from the analysis due to missing data on any of the cardiometabolic conditions (online supplemental figure 1). A sensitivity analysis was performed to assess the impact of excluding these participants; no significant differences were observed, supporting the validity of the main analysis (online supplemental table S1). Individual data on 190 955 participants from India screened in 2017 were not made available after collection due to regulatory reasons.14 When all three BP readings were available, the mean of the second and third BP readings was used for the analyses. Where the second or third BP reading was missing, multiple imputation using chained equations was performed to impute the mean of the second and third BP reading, assuming that the missing BP readings were missing at random conditional on the included covariates. This was performed to reduce bias, as both systolic and diastolic BP are lower on average across repeated readings for the same individual.14,16 Performing multiple imputation on the full dataset across 3 years was not computationally feasible and so we used imputations created in earlier studies: for participants in 2017 and 2018 from Lin et al and for participants in 2019 from Beaney et al.16 19 This resulted in imputations created via models with slightly different covariates for participants in 2019, but each model included participant age, sex, ethnicity, antihypertensive medication use, height and weight (or BMI), alcohol intake, smoking status, along with all other BP and heart rate measurements. Previous analyses from MMM have demonstrated that additional covariates have little impact on the estimation of the mean reading and most of the variation in the mean of the second and third BP reading is explained by the value of the first BP reading.14 Our approach resulted in the inclusion of 25 sets of imputed BP readings for each year, which related to the approximated proportion of participants in each year of the campaign that were missing one or more BP readings. Statistical analysis Results on hypertension parameters are presented before and after standardisation for age and sex; standardisation was based on the WHO single-age world-standard population and assuming an equal female to male ratio.20 21 To examine the association between having CMM and BP, linear mixed models were applied separately for systolic BP and diastolic BP as outcomes, with CMM as the exposure. Three separate models were run for the linear mixed models. The first was a univariable (unadjusted) model. The second model adjusted for age, sex (including an interaction term between age and sex) and antihypertensive medication, based on the significant known effects of these three variables on BP. The third model adjusted for all potential lifestyle factor exposures, including age, sex, antihypertensive medication use, BMI category, smoking and alcohol consumption. All models included a random intercept at country level to account for clustering, under our assumption that participants screened within each country are likely to be more similar to those in other countries independent of other covariates collected. Participants with no cardiometabolic conditions were used as a reference group for all linear mixed models. Data were analysed using STATA V.17.0 (StataCorp). Results Study participants A total of 3 397 746 participants with complete data on comorbidities were included in this analysis (online supplemental figure 1), arising from 105 countries. Of those, 408 162 (12.0%) had at least one cardiometabolic condition and 2 989 584 (88.0%) did not report any. Of those with one or more cardiometabolic conditions, 316 940 (77.7%) had a single condition and 91 222 (22.3%) had CMM. Of those with at least one condition, 15.3% reported a previous MI, 6.9% reported a history of stroke, 55.5% reported having diabetes only, 7.7% had a history of MI and stroke, 5.7% had diabetes and a history of MI, 2.0% had diabetes and a history of stroke and 7.0% had all three conditions (figure 1). Participant distribution among those with one or multiple cardiometabolic conditions. The percentages reported are of those participants with at least one cardiometabolic condition. MI, myocardial infarction. Participant characteristics are presented in table 1 for participants with and without CMM. Participant characteristics for each individual participant subgroup and for the total of all screened participants can be found in the online supplemental table S2. Participants were screened from seven geographic regions, with most participants being screened in South Asia (23.5%) and the least in Northern Africa and Middle East (5.5%) and the most commonly reported ethnicities were East Asian (26.5%) and South Asian (25.6%). Most participants were screened from lower-income countries (59.3%). Participant ages ranged from 18 to 99 years, with a mean of 45.2 (SD 16.8) years. Overall, participants with no cardiometabolic conditions were younger than those with any number of conditions. Females accounted for 53.2% of the total sample, although 50% or less of participants with CMM were female. Approximately half (52.8%) of participants had a healthy weight, and average BMI tended to increase with increasing number of cardiometabolic conditions. Of all screened participants, 12.8% were current smokers but of participants who reported an MI and stroke, and participants with all three conditions, >70% were current smokers. Of all screenees, 10.2% were moderate/heavy alcohol drinkers (alcohol intake once or more a week). Participants with stroke alone had the highest alcohol consumption (19.4% moderate/heavy alcohol usage). Table 1Total number and proportions for baseline characteristics for participants with no CMM and participants with CMM, excluding those with missing information for each individual characteristicCharacteristicsNo CMMCMMN=3 306 524N=91 222World region South Asia789 311 (23.9%)45 308 (49.7%) East Asia710 836 (21.5%)17 452 (19.1%) South-East Asia and Australasia706 158 (21.4%)8014 (8.8%) Americas316 624 (9.6%)5551 (6.1%) Sub-Saharan Africa351 732 (10.6%)1877 (2.1%) Northern Africa and Middle East184 443 (5.6%)2046 (2.2%) Europe247 410 (7.5%)10 974 (12.0%)Country income Lower income1 953 308 (59.1%)61 851 (67.8%) Higher income1 353 216 (40.9%)29 371 (32.2%)Sex Male1 532 729 (46.7%)51 684 (56.9%) Female1 752 593 (53.3%)39 129 (43.1%)Age Mean age (SD)45.1 (16.5)52.1 (16.0) <30 years708 259 (22.6%)12 254 (14.5%) 30–491 178 655 (37.7%)24 182 (28.6%) 50–69993 912 (31.8%)32 977 (39.1%) ≥70247 529 (7.9%)15 005 (17.8%)BMI category Underweight196 404 (6.4%)4944 (5.9%) Healthy weight1 634 246 (53.1%)35 104 (42.2%) Overweight899 094 (29.2%)27 933 (33.6%) Obese346 741 (11.3%)15 173 (18.2%)Ethnicity South Asian761 524 (25.7%)41 633 (48.7%) East Asian815 098 (27.5%)17 884 (20.9%) Black354 479 (12.0%)2572 (3.0%) South-East Asian338 413 (11.4%)3 358 (3.9%) White310 870 (10.5%)11 709 (13.7%) Mixed260 088 (8.8%)6498 (7.6%) Arabic69 469 (2.3%)1164 (1.4%) Other50 302 (1.7%)679 (0.8%)Smoking Non-smoker2 901 057 (88.4%)39 752 (43.7%) Current smoker38 2254 (11.6%)51 127 (56.3%)Alcohol intake Never/rarely2 923 925 (93.7%)83 197 (96.3%) 1 or more a week197 526 (6.3%)3199 (3.7%)BMI, body mass index; CMM, cardiometabolic multimorbidity. Total number and proportions for baseline characteristics for participants with no CMM and participants with CMM, excluding those with missing information for each individual characteristic BMI, body mass index; CMM, cardiometabolic multimorbidity. Co-existence of hypertension with a single cardiometabolic condition and CMM After age and sex standardisation, 988 392 (29.1%) participants were classified as having hypertension. Hypertension was prevalent among 787 816 (26.4%) of those with no cardiometabolic conditions and was more common with an increasing number of conditions, present in 51 202 (56.1%) of those with CMM. Prevalence also varied according to the specific CMM pattern: 47.7% of those with MI and stroke, 56.7% of those with MI and diabetes, 61.9% of those with stroke and diabetes and 63.3% of those with all three conditions (table 2). Table 2Worldwide totals and proportions of participants with hypertension, and percentages on treatment and with controlled BP, after age and sex standardisationParticipant subgroupNHypertensionTreated hypertensivesControlled BP of those on medicationNo cardiometabolic conditions2 989 584 (88.0%)787 816 (26.4%)357 668 (45.4%)259 915 (72.7%)One cardiometabolic condition316 940 (9.3%)149 374 (47.1%)111 581 (74.7%)91 373 (81.9%) MI only62 635 (1.8%)26 019 (41.5%)19 852 (76.3%)17 407 (87.7%) Stroke only27 983 (0.8%)12 807 (45.8%)9592 (74.9%)7314 (76.3%) Diabetes only226 322 (6.7%)110 548 (48.9%)82 137 (74.3%)66 652 (81.1%)Two cardiometabolic conditions62 731 (1.8%)33 158 (52.9%)27 340 (82.5%)20 638 (75.5%) MI and stroke31 455 (0.9%)15 000 (47.7%)12 600 (84.0%)9509 (75.5%) MI and diabetes23 238 (0.7%)13 184 (56.7%)10 771 (81.7%)8221 (76.3%) Stroke and diabetes8038 (0.2%)4974 (61.9%)3969 (79.8%)2908 (73.3%)MI, stroke, and diabetes28 491 (0.8%)18 044 (63.3%)16 474 (91.3%)12 734 (77.3%)Total of those with CMM91 222 (2.6%)51 202 (56.1%)43 814 (85.6%)33 372 (76.2%)Total of all participants3 397 746 (100.0%)988 392 (29.1%)513 063 (51.9%)384 660 (75.0%)BP, blood pressure; CMM, cardiometabolic multimorbidity; MI, myocardial infarction. Worldwide totals and proportions of participants with hypertension, and percentages on treatment and with controlled BP, after age and sex standardisation BP, blood pressure; CMM, cardiometabolic multimorbidity; MI, myocardial infarction. Overall, after age and sex standardisation, of all participants classified as having hypertension, 513 023 (51.9%) were taking antihypertensive medication. The percentage on treatment was lower among those with no cardiometabolic conditions (45.4%) compared with those with CMM (85.6%). Of those with CMM, those with all three conditions were more often on antihypertensive medication than any other participant subgroup (91.3%) (table 2). Among treated hypertensives, control rates were 72.7% in those with no cardiometabolic conditions, 81.9% in those with one condition and 76.2% in those with CMM. Results before age and sex standardisation are presented in the online supplemental table S3. Relationship between single cardiometabolic conditions and CMM with BP Linear mixed models were constructed to explore the relationship between specific cardiometabolic conditions, alone or in combination, and mean BP levels (figures2 3, online supplemental tables S6–S8). As compared with participants with no cardiometabolic conditions, in unadjusted models (model 1), participants with a single condition had higher average systolic BPs, but lower average diastolic BPs (figure 2). After adjustment for age, sex, and antihypertensive medication use (model 2) or after full adjustment (model 3) those with MI only and those with stroke only had lower systolic and diastolic BP. However, participants with diabetes maintained a higher systolic BP across all three models, but a lower average diastolic BP after adjustment (models 2 and 3) (figure 2). Difference in mean systolic and mean diastolic BP in participants with a single cardiometabolic condition as compared with participants with no cardiometabolic conditions. Note: Model 1 refers to an unadjusted model, model 2 refers to a model adjusted for age, sex and use of antihypertensive medication and model 3 refers to a fully adjusted model. A table with all estimates of the linear mixed models can be found in online supplemental tables S6–S8. BP, blood pressure. Difference in mean systolic and mean diastolic BP in participants with CMM as compared with participants with no cardiometabolic conditions. Note: Model 1 refers to an unadjusted model, Model 2 refers to a model adjusted for age, sex and use of antihypertensive medication and Model 3 refers to a fully adjusted model. A table with all estimates of the linear mixed models can be found in online supplemental tables S6–S8. BP, blood pressure; CMM, cardiometabolic multimorbidity. Among participants with different CMM combinations, those with diabetes and either MI or stroke had the highest average systolic BP before and after adjustment, as compared with participants with no cardiometabolic conditions (figure 3; models 1–3). The lowest BPs were found among those with MI and stroke and those with all three conditions, who showed significantly lower average systolic and diastolic BPs before and after adjustment (models 1–3). All findings were statistically significant (p<0.001). Crude results of mean BPs before and after age and sex standardisation are presented in the online supplemental tables S4,S5. Discussion This study of 3.4 million adults from 105 countries screened during the 2017–2019 MMM campaigns showed a graded increase in the prevalence of hypertension from 26.4% to 63.3% as the number of cardiometabolic conditions increased from zero to three. A similarly large, graded effect was apparent on rates of treatment (from 45.5% to 91.3%) among those with hypertension across the range from zero to three cardiometabolic conditions. However, rates of BP control among those treated for hypertension were higher in those with only one cardiometabolic condition than those with none or more than one cardiometabolic condition. Importantly, we also report unique findings of significant differences in hypertension prevalence, treatment and control among those with different single cardiometabolic conditions and among those with different combinations of cardiometabolic conditions.22 Our findings of an almost 40% absolute increase in hypertension prevalence from zero to three cardiometabolic conditions are in keeping with previous reports which report hypertension to be more prevalent among those with multiple cardiovascular conditions.11 12 However, among those with CMM, large differences in hypertension prevalence were apparent across specific combinations of conditions. Notably, those with diabetes in combination with either stroke or MI had significantly higher rates of hypertension than those with MI and stroke combined (table 2). High rates of hypertension in those with diabetes are well established23 24 and are likely attributable to shared pathophysiological mechanisms at both microvascular and macrovascular levels, including obesity, oxidative stress, inflammation, arterial stiffness and insulin resistance.25,27 Common aetiology notwithstanding, the frequent coexistence of hypertension with CMM involving diabetes suggests that a more proactive approach to the measurement and treatment of BP in those with diabetes is warranted. Compared with hypertensive participants with no cardiometabolic conditions, among whom less than half were on BP-lowering treatment, about 75% of those with hypertension and a single condition and about 85% of those with hypertension and CMM were taking antihypertensive medication. This may in part reflect that patients with chronic conditions such as diabetes or established CVD are more prone to an ascertainment bias causing better identification and management of current risk factors such as raised BP.28 Furthermore, such chronic conditions have often attracted lower BP treatment thresholds and targets in guidelines.28 In addition, patients who have suffered an MI are commonly prescribed BP-lowering agents such as beta-blockers and RAS-blockers to reduce the risk of future MACE irrespective of being hypertensive or not.29 30 Among treated hypertensive participants, those with no cardiometabolic conditions had lower BP control rates than those with any single condition but were similar to rates among those with two or more conditions. However, absolute differences in control rates were relatively small among different combinations of conditions. The highest control rates were in those with a history of MI only, which is possibly commensurate with the routine use of BP-lowering agents for such patients who are not necessarily hypertensive but meet the criteria for classification here as ‘hypertensive’. Among participants with one cardiometabolic condition, those with a history of stroke presented the lowest rates of controlled BP, which might be explained by higher levels of pre-existing BP or treatment-resistant hypertension contributing to a stroke and so representing a group with more difficult to manage hypertension. Furthermore, evidence suggests that stroke survivors often have inadequate follow-up and have suboptimal BP control due to therapeutic inertia and poor medication adherence.19 31 Regardless of differences in control rates, BP control was suboptimal for all screenees with hypertension. Compared with those who had no cardiometabolic conditions, the average BPs varied among those with a single cardiometabolic condition and among those with combinations of conditions (figures2 3). While unadjusted systolic BPs associated with all three single conditions were significantly increased, and especially in those with diabetes, after adjustment, only among those with diabetes did systolic BP remain elevated. Among those with CMM, and compared with those with no cardiometabolic condition, adjusted systolic BPs were only significantly higher among those with diabetes and either MI or stroke, for whom hypertension rates were highest among cardiometabolic condition combinations (table 2). Once again, these data suggest that hypertension detection and BP treatment should be intensified when comorbidities exist but particularly among those with diabetes. Strengths This study used data derived from over 100 countries, representing a wide range of ethnicities and ages, including 408 162 participants with one or more cardiometabolic conditions, and 91 222 with CMM. Most research on multimorbidity focuses on older populations and is based on small sample sizes, whereas this study provides one of the largest datasets of its type, including parts of the world which are often under-represented in studies of CMM. This allows for analyses of associations with risk factors and parameters of hypertension control in people with multimorbidity across a wide spectrum of age and race. Furthermore, it includes three specific cardiometabolic conditions (MI, stroke and diabetes) which are considered to be the most prevalent conditions in CMM. This study investigates the number and combination of conditions, as compared with most studies on multimorbidity which focus on a binary definition of the presence or absence of multiple coexisting conditions. As a result, this study is innovative in describing the burden of hypertension in those suffering from various combinations of CMM and showing substantial differences in hypertension prevalence, treatment and BP control rates, according to the specific combination of conditions. Limitations This study has several limitations. First, study participants were self-selected through opportunistic convenience sampling during the MMM campaigns, and hence the study was not designed to provide representative samples. However, while the campaigns do not evaluate the true prevalence of hypertension, associations within the databases are considered valid.32 Although direct comparison to national prevalence data for each country would help assess generalisability, for most of the low- and middle-income settings included in MMM, reliable population-level estimates are lacking, particularly for multimorbidity data. However, examples from some countries support the representativeness of MMM estimates to national prevalence,33 34 while across all MMM countries, parameters of hypertension treatment and control are strongly associated with stroke mortality at a national level.19 Nevertheless, it is feasible that genuine differences in our findings may be apparent across different regions and merit further investigations. Second, data on stroke, MI and diabetes were self-reported and therefore did not include fatal events nor information on the date of diagnosis and may include some misclassifications of diagnosis—particularly of diabetes. As a result of the cross-sectional design, it is not possible to determine the time sequence of associations observed, that is, whether the presence of cardiometabolic conditions/CMM was a cause or a consequence of hypertension. Additionally, data on the type of stroke, MI and diabetes were not collected, making it impossible to assess the degree and severity of these conditions. Third, self-reported data on other common cardiometabolic conditions, such as chronic kidney disease, were not collected in the MMM campaigns of 2017–2019 and are therefore not included in this study; however, some of these conditions will be collected in future campaigns. Fourth, this study makes a distinction between hypertension and other cardiometabolic conditions to explore the burden of hypertension in multimorbid participants and includes raised BP as a risk factor. However, hypertension is often included in multimorbidity studies as an additional cardiovascular condition adding to the multimorbid status rather than as a separate condition. Fifth, data on lifestyle factors, including importantly smoking and alcohol intake, were also self-reported and or limited in detail such as dose and duration of exposure, which could lead to either an underestimation or overestimation of certain responses. However, self-reporting of lifestyle factors through questionnaires is common practice in large epidemiological studies. Lastly, hypertension in this study is defined based on a single set of three BP readings or being on antihypertensive treatment. In clinical practice, it is recommended that hypertension be determined after taking at least two sets of readings,35 so this study is likely to include an overestimation of the actual rate of true hypertension. Furthermore, the definition of hypertension in this study included those on BP-lowering treatment, which may have been prescribed for conditions other than raised BP. Conclusions Global data from MMM demonstrates the high burden of hypertension among people with cardiometabolic conditions, with a graded increase in prevalence with an increasing number of conditions. Although those with CMM were more likely to be treated for their hypertension compared with those with no cardiometabolic conditions or only a single condition, 15% were not on any BP-lowering medication and a quarter of those who were treated were not controlled, underscoring the need for more proactive care in these higher-risk groups. Improvements in the diagnosis, treatment and control of hypertension are urgent global requirements.910 14,16 Particularly for those with co-existing cardiometabolic conditions who may already be aware of having hypertension, focused efforts are needed to intensify BP-lowering treatment to reduce their risk of future cardiovascular events. Supplementary material Acknowledgements We thank all the many volunteer MMM staff and participants contributing to the campaigns. We are also grateful to Omron for the donations of blood pressure devices. TB acknowledges support from the National Institute for Health and Care Research Imperial Biomedical Research Centre. Servier had no role in study design, data collection, data analysis, data interpretation or writing of the report. Footnotes Funding: The May Measurement campaigns in 2017–2019 were funded by the International Society of Hypertension and Servier Pharmaceuticals. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Where required, ethics approvals for the MMM campaign were secured by national investigators in each participating country. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability free text: The data used in this study are available for research purposes on approval from the May Measurement Month Management Board (https://maymeasure.org/about/). For further information or to request access, please contact the corresponding authors TB. Data availability statement Data are available on reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available on reasonable request.